Janus Henderson Group PLC Compass Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$178 Billion
Q1 2024

A detailed history of Janus Henderson Group PLC transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,492,900 shares of CMPX stock, worth $6.88 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

6,492,900

Previous 6,547,231 0.83%

Holding current value

$6.88 Million

Previous $10.2 Million 25.87%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.2 - $2.29 $65,197 - $124,417	-54,331 Reduced 0.83%	6,492,900 $12.9 Million
Q4 2023 Feb 14, 2024	SELL	$1.4 - $1.98 $158,769 - $224,545	-113,407 Reduced 1.7%	6,547,231 $10.2 Million
Q3 2023 Nov 14, 2023	BUY	$1.87 - $3.25 $826,347 - $1.44 Million	441,897 Added 7.11%	6,660,638 $13.1 Million
Q2 2023 Aug 14, 2023	BUY	$2.64 - $3.48 $565,667 - $745,652	214,268 Added 3.57%	6,218,741 $19.8 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $204,674 - $357,202	65,183 Added 1.1%	6,004,473 $19.6 Million

Q4 2022 Feb 14, 2023	BUY	$2.55 - $5.41 $6.16 Million - $13.1 Million	2,416,310 Added 68.59%	5,939,290 $29.9 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $334,037 - $592,476	175,809 Added 5.25%	3,522,980 $8.07 Million
Q2 2022 Aug 15, 2022	BUY	$1.43 - $3.1 $220,044 - $477,018	153,877 Added 4.82%	3,347,171 $8.8 Million
Q1 2022 May 16, 2022	BUY	$1.25 - $3.5 $2.15 Million - $6.02 Million	1,720,683 Added 116.85%	3,193,294 $4.33 Million
Q4 2021 Feb 14, 2022	BUY	$2.88 - $3.98 $4.24 Million - $5.86 Million	1,472,611 New	1,472,611 $4.7 Million

Others Institutions Holding CMPX

# of Institutions

Shares Held

94.2M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $107M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Compass Therapeutics, Inc. Transaction History